1240305-17-2
Chemical Structure
SGL5213
- CAS No.: 1240305-17-2
- Formula:C37H55N3O8
- Molecular Weight:669.85
IUPAC Name: (E)-N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-isopropyl-4-methoxy-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)-2,2-dimethylbut-3-enamide
InChIKey: MUBBPBZRFJGZEU-XSPPBVGUSA-N
SMILES: COC1=C([C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)CO)C=C(CC3=CC=C(/C=C/C(C)(C)C(NC(C)(C)C(NCCN(C)C)=O)=O)C=C3)C(C(C)C)=C1
Biological Activity: SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SGL5213 | SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
